A Pharmacor Analyst Call from Decision Resources

To ensure that our emails get to your inbox, please add Decision_Resources@mail.vresp.com to your email address book or safe senders list.
PLEASE DO NOT REPLY TO THIS EMAIL; CONTACT YOUR ACCOUNT REPRESENTATIVE DIRECTLY.

If this message does not display properly, please click here to launch your browser.

Avastin and Other Key Emerging Agents Are Poised to Change the Landscape of Ovarian Cancer Treatment – News from ASCO

Based on our Pharmacor advisory service entitled Ovarian Cancer, Decision Resources is offering an exclusive analyst call entitled Avastin and Other Key Emerging Agents Are Poised to Change the Landscape of Ovarian Cancer Treatment – News from ASCO. Because this presentation will feature updates to the Ovarian Cancer topic, it is ONLY available to purchasers of this Pharmacor advisory service.

Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.

Given the poor prognosis and significant unmet need for new treatment options, ovarian cancer has become an increasing focus for research and development by drug manufacturers. Earlier this month, the much anticipated Phase III clinical trial results of Roche/Genentech/Chugai’s Avastin in ovarian cancer were presented at the 2010 American Society of Clinical Oncology (ASCO) general meeting, highlighting the agent’s potential in the first-line ovarian cancer setting. In light of these and previously published data, Decision Resources anticipates that Avastin will be the first ever targeted therapy to enter the ovarian cancer market in 2011. Further encouraging data in ovarian cancer presented at ASCO, including results of Eisai’s farletuzumab, AstraZeneca’s olaparib, Amgen’s AMG-386 and Sunesis’ voreloxin, suggest further dramatic change within the ovarian cancer treatment landscape is imminent.

This 15-minute analyst call, presented by Decision Resources Analyst Niamh Murphy, Ph.D., will answer the following questions:

What do interviewed experts consider about the potential for bevacizumab in ovarian cancer?
What other novel agents are likely to enter the ovarian cancer market within the next ten years?
What is Decision Resources’ sales forecast in the world’s major markets through 2018 for bevacizumab and other novel agents in ovarian cancer?

Dr. Murphy will conduct a live Q & A session following the presentation.

Registration

Avastin and Other Key Emerging Agents Are Poised to Change the Landscape of Ovarian Cancer Treatment - News from ASCO

June 24, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Date & Time
Thursday, June 24, 2010
10 a.m. U.S. Eastern Time,
4 p.m. Central European Time

Duration
15 minutes

Niamh Murphy, Ph.D., is an analyst on the oncology team at Decision Resources. Dr. Murphy obtained an honors degree in biotechnology and a Ph.D. on the molecular biology of cervical cancer from Trinity College in Ireland. She worked as a postdoctoral scientist for several years, during which time she was involved in several international translational breast cancer research projects. Most recently, she analyzed drug resistance and chromosomal instability in breast cancer. Dr. Murphy authored numerous peer-reviewed papers and abstracts and presented data at international cancer conferences.

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.